Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Merck Sterile Product Manufacturing Difficulties Affect Cancidas, Timoptic

Dec 10 2001

• By The Pink Sheet

Related Content

Merck West Point Timeliness Of Corrective Actions Cited In FDA Letter

Jul 13 1998

Wyeth Will Lose 18.5% Of Marietta Sales If Firm Does Not Comply With GMPs

Oct 09 2000

Vioxx GMP Violations Cited In FDA Warning Letter Spur Merck Retraining

Jul 17 2000

Vfend Use In Febrile Neutropenia Should Be Limited To High-Risk Patients

Oct 08 2001

Lilly Consultants To Pre-Inspect Zovant Contract Manufacturing Sites

Apr 23 2001

Merck Will Study Cancidas/Antifungal Combinations In Phase IV Trials

Feb 05 2001

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window